Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

. 2016 Jun ; 11 (3) : 383-400.

Jazyk angličtina Země Francie Médium print

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid26706237
Odkazy

PubMed 26706237
DOI 10.1007/s11523-015-0402-9
PII: 10.1007/s11523-015-0402-9
Knihovny.cz E-zdroje

The aim of this post hoc analysis of the VELOUR study (ClinicalTrials.gov NCT00561470) was to investigate the treatment effect of adding aflibercept to second-line infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) in patients with metastatic colorectal cancer (mCRC) who had failed any prior oxaliplatin-containing regimen. Adjuvant rapid relapsers (ARR), who were enrolled directly following relapse during or within 6 months of completion of oxaliplatin-containing adjuvant chemotherapy (N = 124, including 17 patients who also received bevacizumab as part of their adjuvant therapy), were excluded from the original VELOUR intention-to-treat (ITT) population (N = 1226). After exclusion of the ARR, overall survival (OS) in the ITT minus ARR (ITT-ARR) population (N = 1102) was longer in the aflibercept plus FOLFIRI arm than in the placebo plus FOLFIRI arm [hazard ratio (HR) 0.78, 95 % confidence interval (CI) 0.68-0.90; median survival difference 1.87 months]. In the subgroup of patients assigned to the prior bevacizumab stratum at randomization, OS was numerically longer in the aflibercept plus FOLFIRI arm than in the placebo plus FOLFIRI arm (HR 0.81; 95 % CI 0.63-1.04; median survival difference 2.14 months). Comparison of the post hoc analysis results with the primary analysis from VELOUR suggests that the inclusion of the directly enrolled ARR may have understated the aflibercept treatment benefit for both bevacizumab-pretreated and bevacizumab-naïve patients in the strictly second-line setting although no definitive conclusion may be inferred. The benefit associated with the addition of aflibercept to second-line FOLFIRI in patients with mCRC was observed whatever the timing of first-line disease progression. There were no unexpected safety concerns.

Zobrazit více v PubMed

Br J Cancer. 2013 Jun 25;108(12):2549-56 PubMed

Angiogenesis. 2012 Jun;15(2):171-85 PubMed

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 PubMed

Lancet Oncol. 2015 May;16(5):499-508 PubMed

Nat Med. 2001 May;7(5):575-83 PubMed

Ann Oncol. 2015 Apr;26(4):724-30 PubMed

J Clin Oncol. 2008 May 10;26(14):2336-41 PubMed

N Engl J Med. 2004 Jun 3;350(23 ):2335-42 PubMed

Lancet Oncol. 2013 Jan;14(1):29-37 PubMed

BMC Cancer. 2014 Aug 20;14:605 PubMed

Eur J Cancer. 2015 Jan;51(1):18-26 PubMed

J Clin Oncol. 2010 May 1;28(13):2137-43 PubMed

Clin Cancer Res. 2013 Apr 15;19(8):1920-5 PubMed

Clin Med Insights Oncol. 2013 Jun 06;7:123-35 PubMed

J Clin Oncol. 2012 Oct 1;30(28):3499-506 PubMed

J Clin Oncol. 2007 Apr 20;25(12):1539-44 PubMed

Lancet. 2007 Dec 22;370(9605):2103-11 PubMed

PLoS One. 2013 Oct 15;8(10):e77117 PubMed

J Clin Oncol. 2008 Nov 20;26(33):5326-34 PubMed

Br J Cancer. 2013 Dec 10;109(12):3127-9 PubMed

Ann Oncol. 2012 Oct;23(10):2479-516 PubMed

JAMA. 2009 Dec 2;302(21):2338-44 PubMed

Eur J Cancer. 2014 Jan;50(2):320-31 PubMed

J Clin Oncol. 2011 Jan 1;29(1):1-4 PubMed

Oncologist. 2012;17 (12 ):1486-95 PubMed

Br J Cancer. 2011 Apr 12;104(8):1270-7 PubMed

N Engl J Med. 2006 Dec 14;355(24):2542-50 PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00561470

Najít záznam

Citační ukazatele

Možnosti archivace